BACKGROUND AND PURPOSE: For palliative care of spinal bone metastases, stability assessment is of crucial importance. Pathological fractures, instability-related patient immobility and the extent of bone metastasis have been reported to affect patient outcome and these parameters have therefore been used for treatment stratification. We report on stability-dependent fracture and survival rates in over 300 non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: Data from 303 patients with 868 osteolytic metastases treated with radiotherapy (RT) between 2000 and 2012 were evaluated retrospectively. RESULTS: In NSCLC patients with bone metastases only, the retrospective 6- and 12-month overall survival (OS) rates were 76.7 and 47.2%, respectively. In patients with additional non-bone distant metastases, these values were 60.0 and 34.0%, respectively. Survival rates were significantly lower in patients with multiple bone metastases and in those suffering pathological fractures (p=0.017). No significant impact of histological type, location of spinal lesions or treatment regime was detected. Furthermore, stability assessment revealed no influence of vertebral column stability on patient outcome (p=0.739). CONCLUSION: Our analysis demonstrated a correlation between the pathological fractures of bone lesions, the number of bone metastases, additional distant metastases and survival. The results offer a rationale for future prospective investigations.
BACKGROUND AND PURPOSE: For palliative care of spinal bone metastases, stability assessment is of crucial importance. Pathological fractures, instability-related patient immobility and the extent of bone metastasis have been reported to affect patient outcome and these parameters have therefore been used for treatment stratification. We report on stability-dependent fracture and survival rates in over 300 non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: Data from 303 patients with 868 osteolytic metastases treated with radiotherapy (RT) between 2000 and 2012 were evaluated retrospectively. RESULTS: In NSCLCpatients with bone metastases only, the retrospective 6- and 12-month overall survival (OS) rates were 76.7 and 47.2%, respectively. In patients with additional non-bone distant metastases, these values were 60.0 and 34.0%, respectively. Survival rates were significantly lower in patients with multiple bone metastases and in those suffering pathological fractures (p=0.017). No significant impact of histological type, location of spinal lesions or treatment regime was detected. Furthermore, stability assessment revealed no influence of vertebral column stability on patient outcome (p=0.739). CONCLUSION: Our analysis demonstrated a correlation between the pathological fractures of bone lesions, the number of bone metastases, additional distant metastases and survival. The results offer a rationale for future prospective investigations.
Authors: D Rades; S Douglas; T Veninga; A Bajrovic; L J A Stalpers; P J Hoskin; V Rudat; S E Schild Journal: Strahlenther Onkol Date: 2012-02-25 Impact factor: 3.621
Authors: M Niewald; H J Tkocz; U Abel; T Scheib; K Walter; C Nieder; K Schnabel; W Berberich; R Kubale; M Fuchs Journal: Int J Radiat Oncol Biol Phys Date: 1996-12-01 Impact factor: 7.038
Authors: Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Ingmar Schlampp; Stefan Rieken; Daniel Habermehl; Thomas Bruckner; Robert Förster; Jürgen Debus; Harald Rief Journal: Strahlenther Onkol Date: 2014-04-01 Impact factor: 3.621
Authors: Eva Meyerhof; Tanja Sprave; Stefan Ezechiel Welte; Nils H Nicolay; Robert Förster; Tilman Bostel; Thomas Bruckner; Ingmar Schlampp; Jürgen Debus; Harald Rief Journal: Trials Date: 2017-03-03 Impact factor: 2.279
Authors: Harald Rief; Maximiliane Heinhold; Thomas Bruckner; Ingmar Schlampp; Robert Förster; Thomas Welzel; Tilman Bostel; Jürgen Debus; Stefan Rieken Journal: Radiat Oncol Date: 2014-06-11 Impact factor: 3.481
Authors: Robert J Wolf; Robert Foerster; Thomas Bruckner; Tilman Bostel; Ingmar Schlampp; Juergen Debus; Harald Rief; German Bone Research Group Journal: BMC Cancer Date: 2016-07-25 Impact factor: 4.430